Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2024-11-02 DOI:10.1007/s12325-024-03002-9

Swarna Khare, Beatrice Osumili, Nele Debackere, Karabo Keapoletswe, Serena Falato, Thomas Raoul, Briana Coles

{"title":"Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.","authors":"Swarna Khare, Beatrice Osumili, Nele Debackere, Karabo Keapoletswe, Serena Falato, Thomas Raoul, Briana Coles","doi":"10.1007/s12325-024-03002-9","DOIUrl":null,"url":null,"abstract":"Introduction: Type 2 diabetes mellitus (T2DM) is a complex metabolic disease with several treatment options. Some glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the European Medicines Agency include dulaglutide, subcutaneous (s.c.) semaglutide, and oral semaglutide. This study examines dulaglutide and semaglutide dosing patterns for T2DM in France and Italy.Methods: IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022. Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.Results: In France and Italy, 255,571 and 350,853 patients, respectively, received at least one study GLP-1 RA. Most dulaglutide-naïve patients in France (62%) and approximately half in Italy (49%) started on 1.5 mg and remained on this dose for up to 12 months (France: 66% cohort 1, 88% cohort 2; Italy: 73% cohort 1, 87% cohort 2). In cohort 1, s.c. semaglutide users mostly started on 0.25 mg (France, 78%; Italy, 61%). At 12 months, s.c. semaglutide 1.0 mg was most prescribed (France: 58% cohort 1, 75% cohort 2; Italy: 59% cohort 2), with cohort 1 in Italy mostly receiving 0.5 mg (57%). Most oral semaglutide users in Italy started on 3.0 mg (78% cohort 1; 68% cohort 2), which was increased to 7.0 mg (62% cohort 1) and 14.0 mg (48% cohort 2) at 12 months.Conclusions: GLP-1 RA dosing patterns, although similar between France and Italy, were heterogeneous over time. As oral semaglutide and higher dulaglutide doses are recent to the market, additional real-world evidence is required to evaluate utilization patterns. Graphical abstract available for this article.","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-024-03002-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a complex metabolic disease with several treatment options. Some glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the European Medicines Agency include dulaglutide, subcutaneous (s.c.) semaglutide, and oral semaglutide. This study examines dulaglutide and semaglutide dosing patterns for T2DM in France and Italy.

Methods: IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022. Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.

Results: In France and Italy, 255,571 and 350,853 patients, respectively, received at least one study GLP-1 RA. Most dulaglutide-naïve patients in France (62%) and approximately half in Italy (49%) started on 1.5 mg and remained on this dose for up to 12 months (France: 66% cohort 1, 88% cohort 2; Italy: 73% cohort 1, 87% cohort 2). In cohort 1, s.c. semaglutide users mostly started on 0.25 mg (France, 78%; Italy, 61%). At 12 months, s.c. semaglutide 1.0 mg was most prescribed (France: 58% cohort 1, 75% cohort 2; Italy: 59% cohort 2), with cohort 1 in Italy mostly receiving 0.5 mg (57%). Most oral semaglutide users in Italy started on 3.0 mg (78% cohort 1; 68% cohort 2), which was increased to 7.0 mg (62% cohort 1) and 14.0 mg (48% cohort 2) at 12 months.

Conclusions: GLP-1 RA dosing patterns, although similar between France and Italy, were heterogeneous over time. As oral semaglutide and higher dulaglutide doses are recent to the market, additional real-world evidence is required to evaluate utilization patterns. Graphical abstract available for this article.

查看原文本刊更多论文

法国和意大利 2 型糖尿病患者服用度拉鲁肽和赛马鲁肽的剂量模式：回顾性队列研究

简介2 型糖尿病（T2DM）是一种复杂的代谢性疾病，有多种治疗方案可供选择。欧洲药品管理局批准的一些胰高血糖素样肽 1 受体激动剂（GLP-1 RA）包括度拉鲁肽、皮下注射（s.c. ）塞马鲁肽和口服塞马鲁肽。本研究探讨了法国和意大利治疗 T2DM 的度拉鲁肽和塞马鲁肽用药模式：IQVIA纵向处方数据确定了2020年8月1日至2022年12月31日期间开具度拉鲁肽或赛马鲁肽处方的T2DM成人患者。对队列 1（事件）和队列 2（流行）用户进行了为期 12 个月的跟踪调查：在法国和意大利，分别有 255,571 名和 350,853 名患者接受了至少一项 GLP-1 RA 研究。法国大多数（62%）和意大利约半数（49%）未接受过度拉鲁肽治疗的患者开始服用1.5毫克，并在长达12个月的时间里一直服用该剂量（法国：66%队列1，88%队列2；意大利：73%队列1，87%队列2）。在队列 1 中，大部分使用西药塞马鲁肽的患者一开始服用的剂量为 0.25 毫克（法国：78%；意大利：61%）。12 个月时，处方量最多的是 1.0 毫克的西格列汀（法国：58% 的队列 1，75% 的队列 2；意大利：59% 的队列 2），意大利队列 1 的处方量大多为 0.5 毫克（57%）。意大利大多数口服塞马鲁肽的患者开始时服用3.0毫克（78%的队列1；68%的队列2），12个月后增至7.0毫克（62%的队列1）和14.0毫克（48%的队列2）：法国和意大利的 GLP-1 RA 用药模式虽然相似，但随着时间的推移却不尽相同。由于口服塞马鲁肽和更高剂量的度拉鲁肽刚上市不久，因此需要更多真实世界的证据来评估使用模式。本文有图表摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.